Larimar Therapeutics Inc (OQ:LRMR)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Tel: N/A
IR: See website
Key People
Carole Ben-Maimon
President, Chief Executive Officer, Director
Michael Celano
Chief Financial Officer, Company Secretary
Business Overview
Larimar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its cell penetrating peptide technology platform. The Company's protein replacement therapy platform is intended to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that are ineffective or have no treatments available. Its cell penetrating peptide (CPP) technology platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company's lead product candidate, CTI-1601, is a recombinant fusion protein intended to deliver human frataxin (FXN), an essential protein to the mitochondria of patients with Friedreich's ataxia. CTI-1601 is in a Phase I clinical program.
Financial Overview
For the six months ended 30 June 2022, Larimar Therapeutics Inc revenues was not reported. Net loss decreased 29% to $17.6M. Lower net loss reflects Research and Development decrease of 41% to $10.1M (expense), General and administrative decrease of 17% to $4.2M (expense), Other income, net decrease of 25% to $36K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.54 to -$0.96.
Employees: 31 as of Feb 1, 2022
Reporting Currency: U.S. Dollars
Enterprise value: $72.87M as of Jun 30, 2022
Annual revenue (TTM): $0.00M as of Jun 30, 2022
EBITDA (TTM): -$43.00M as of Jun 30, 2022
Net annual income (TTM): -$43.55M as of Jun 30, 2022
Free cash flow (TTM): -$35.44M as of Jun 30, 2022
Net Debt Last Fiscal Year: N/A
Shares outstanding: 39,935,450 as of Sep 13, 2022
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.